The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has jumped by 14.21% compared to previous close of $1.83. Despite this, the company has seen a gain of 13.59% in its stock price over the last five trading days. prnewswire.com reported 2025-05-27 that Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.
Is It Worth Investing in Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Right Now?
GLMD has 36-month beta value of 0.58. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for GLMD is 2.19M, and currently, short sellers hold a 3.06% ratio of that float. The average trading volume of GLMD on July 09, 2025 was 1.76M shares.
GLMD’s Market Performance
GLMD’s stock has seen a 13.59% increase for the week, with a 40.27% rise in the past month and a 55.97% gain in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are at 7.13% for Galmed Pharmaceuticals Ltd The simple moving average for the past 20 days is 18.26% for GLMD’s stock, with a -21.88% simple moving average for the past 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at 36.36% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.22% of loss for the given period.
Stock Fundamentals for GLMD
The total capital return value is set at -0.36. Equity return is now at value -49.58, with -44.25 for asset returns.
Currently, EBITDA for the company is -7.42 million with net debt to EBITDA at 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.02.
Conclusion
To put it simply, Galmed Pharmaceuticals Ltd (GLMD) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
